tradingkey.logo

Cellectar Biosciences Inc <CLRB.OQ> expected to post a loss of 16 cents a share - Earnings Preview

ReutersMay 9, 2025 2:53 PM
  • Cellectar Biosciences Inc CLRB.OQ CLRB.O is expected to show no change in quarterly revenue when it reports results on May 13 for the period ending March 31 2025

  • ​LSEG's mean analyst estimate for Cellectar Biosciences Inc is for a loss of 16 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Cellectar Biosciences Inc is $3.00​, above​ its last closing price of $0.25. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.34

-0.35

-0.06

Beat

83

Sep. 30 2024

-0.43

-0.37

-0.40

Missed

-7.4

Jun. 30 2024

-0.31

-0.34

-0.03

Beat

91.3​

Mar. 31 2024

-0.56

-0.56

-0.74

Missed

-31.4

​​Dec. 31 2023

-0.78

-0.57

-0.61

Missed

-7

Sep. 30 2023

-0.59

-0.52

-0.83

Missed

-58.1​

Jun. 30 2023

-0.66

-0.64

-0.73

Missed

-14.7

Mar. 31 2023

-0.86

-0.87

-0.76

Beat

12.4

This summary was machine generated May 9 at 14:53 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI